Artykov AA - Search Results

1

DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.

Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA, Plotnikova EA, Pankratov AA, Kirpichnikov MP, Gasparian ME, Dolgikh DA. Yagolovich AV, et al. Among authors: artykov aa. Int J Mol Sci. 2022 Oct 21;23(20):12687. doi: 10.3390/ijms232012687. Int J Mol Sci. 2022. PMID: 36293545 Free PMC article.

2

A New Efficient Method for Production of Recombinant Antitumor Cytokine TRAIL and Its Receptor-Selective Variant DR5-B.

Yagolovich AV, Artykov AA, Dolgikh DA, Kirpichnikov MP, Gasparian ME. Yagolovich AV, et al. Among authors: artykov aa. Biochemistry (Mosc). 2019 Jun;84(6):627-636. doi: 10.1134/S0006297919060051. Biochemistry (Mosc). 2019. PMID: 31238862 Free article.

3

Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile.

Yagolovich AV, Artykov AA, Karmakova TA, Vorontsova MS, Pankratov AA, Andreev-Andrievsky AA, Dolgikh DA, Kirpichnikov MP, Gasparian ME. Yagolovich AV, et al. Among authors: artykov aa. Transl Oncol. 2020 Apr;13(4):100762. doi: 10.1016/j.tranon.2020.100762. Epub 2020 Mar 27. Transl Oncol. 2020. PMID: 32224450 Free PMC article.

4

Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors.

Аrtykov АА, Belov DA, Shipunova VO, Trushina DB, Deyev SM, Dolgikh DA, Kirpichnikov MP, Gasparian ME. Аrtykov АА, et al. Cancers (Basel). 2020 Apr 30;12(5):1129. doi: 10.3390/cancers12051129. Cancers (Basel). 2020. PMID: 32365976 Free PMC article.

5

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells.

Yagolovich A, Kuskov A, Kulikov P, Kurbanova L, Bagrov D, Artykov A, Gasparian M, Sizova S, Oleinikov V, Gileva A, Kirpichnikov M, Dolgikh D, Markvicheva E. Yagolovich A, et al. Pharmaceutics. 2021 Sep 7;13(9):1413. doi: 10.3390/pharmaceutics13091413. Pharmaceutics. 2021. PMID: 34575490 Free PMC article.

6

Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.

Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME. Artykov AA, et al. Front Cell Dev Biol. 2021 Sep 30;9:733688. doi: 10.3389/fcell.2021.733688. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34660590 Free PMC article.

7

Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.

Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME. Artykov AA, et al. Front Cell Dev Biol. 2022 Feb 14;9:820069. doi: 10.3389/fcell.2021.820069. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35237612 Free PMC article.

8

Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.

Yagolovich AV, Artykov AA, Isakova AA, Vorontsova YV, Dolgikh DA, Kirpichnikov MP, Gasparian ME. Yagolovich AV, et al. Among authors: artykov aa. Int J Mol Sci. 2022 May 24;23(11):5860. doi: 10.3390/ijms23115860. Int J Mol Sci. 2022. PMID: 35682540 Free PMC article.

9

Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli.

Isakova A, Artykov A, Vorontsova Y, Dolgikh D, Kirpichnikov M, Gasparian M, Yagolovich A. Isakova A, et al. Mol Biotechnol. 2023 Apr;65(4):581-589. doi: 10.1007/s12033-022-00561-6. Epub 2022 Sep 12. Mol Biotechnol. 2023. PMID: 36094644

10

ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL.

Mishukov A, Odinokova I, Mndlyan E, Kobyakova M, Abdullaev S, Zhalimov V, Glukhova X, Galat V, Galat Y, Senotov A, Fadeev R, Artykov A, Gasparian ME, Solovieva M, Beletsky I, Holmuhamedov E. Mishukov A, et al. Int J Mol Sci. 2022 Dec 8;23(24):15551. doi: 10.3390/ijms232415551. Int J Mol Sci. 2022. PMID: 36555190 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters